Key facts
- Numab Therapeutics’s last known valuation is $100.1M (Mar 2020).
- It has raised $228.1M.
- Notable investors include Mitsubishi UFJ Capital, Novo Holdings, BlackRock, Cormorant Asset Management, Forbion — 15 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 15 names
- ·Watchlist + deal alerts for Numab Therapeutics
- ·The full record, as it builds
Funding rounds
No funding rounds for Numab Therapeutics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Numab Therapeutics
Operator of a biopharmaceutical company intended to develop multispecific antibody-based immunotherapies. The company reduces the random nature of the discovery process to predictably yield ready-to-develop multispecific biotherapeutics through creating mono- or multispecific antibody fragment-based therapeutics with tailored pharmacokinetic properties, enabling healthcare industries to access their platform for simultaneously engaging multiple targets for chronic inflammation and cancer.
- Sector
- Healthcare
- HQ
- Horgen, Switzerland
- Founded
- 2011
- Employees
- 68
- Website
- numab.com/
- Ownership
- Privately Held (backing)
Numab Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Numab Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Numab Therapeutics in its N-PORT filings yet. We sweep new filings monthly.